The Future of Immunotherapies in Advanced/Recurrent Endometrial Cancer Treatment

Video

Experts explain what they are looking forward to in the future of treatment for patients with ER/PR+ and P53 wild-type or mutated advanced/recurrent endometrial cancer.

Recent Videos
Findings from the OVARIO study show that patients with HRR–deficient and BRCA-mutated disease benefitted the most from niraparib/bevacizumab maintenance.
Select comorbidities, ECOG status, and the receipt of radiation were among the differences between a real-world cohort and the RUBY trial population.
Next-generation clinical trials may address when to use CDK4/6 inhibition in patients with low-grade serous ovarian cancer.
The NRG-GY019 trial will assess chemotherapy plus letrozole vs letrozole alone as a frontline treatment for patients with low-grade serous ovarian cancer.
Nearly 40% of low-grade serous ovarian cancers have RAS alterations, which are predominately KRAS mutations.
Related Content
The phase 3 ROSELLA trial results assessing relacorliant/nab-paclitaxel in patients with platinum-resistant ovarian cancer will support an upcoming NDA.

Relacorilant/Chemo Show Survival Benefit in Platinum-Resistant Ovarian Cancer

Roman Fabbricatore
April 2nd 2025
Article

The phase 3 ROSELLA trial results assessing relacorliant/nab-paclitaxel in patients with platinum-resistant ovarian cancer will support an upcoming NDA.

Low grade serous ovarian cancer, a rare epithelial ovarian cancer subtype, requires differentiated treatment from its high-grade counterpart.

Redefining the Treatment Paradigm in Low Grade Serous Ovarian Cancer

Kathleen N. Moore, MD, MS
March 17th 2025
Podcast

Low grade serous ovarian cancer, a rare epithelial ovarian cancer subtype, requires differentiated treatment from its high-grade counterpart.

Social Determinants of Health Negatively Affected Endometrial Cancer Diagnosis

Social Determinants of Health Negatively Affected Endometrial Cancer Diagnosis

Tim Cortese
March 19th 2025
Article

Factors such as language spoken, social vulnerability index characteristics, and insurance type were found to alter endometrial cancer diagnoses and led to worse outcomes.

Uterine transposition, a surgical approach preserving fertility by moving the uterus out of the radiation field, may improve gynecologic cancer outcomes.

Uterine Transposition May Maintain Fertility Following Pelvic Radiotherapy

John Paul Diaz, MD
November 4th 2024
Podcast

Uterine transposition, a surgical approach preserving fertility by moving the uterus out of the radiation field, may improve gynecologic cancer outcomes.

Certain subpopulations experienced significantly poorer outcomes in 2020, highlighting concerns regarding access to care.

Vulvar Cancer Survival Discrepancies Seen in Year 1 of COVID-19 Pandemic

Roman Fabbricatore
March 19th 2025
Article

Certain subpopulations experienced significantly poorer outcomes in 2020, highlighting concerns regarding access to care.

Niraparib/Bevacizumab Maintenance Prolongs Response in Pretreated Ovarian Cancer

Niraparib/Bevacizumab Maintenance Prolongs Response in Pretreated Ovarian Cancer

Ariana Pelosci
March 18th 2025
Article

Results from the NIRVANA-R trial found niraparib/bevacizumab maintenance yielded positive activity in pretreated ovarian cancer.